• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

激酶结构域的 allo 靶向:计算研究的见解及与实验的比较。

Allo-targeting of the kinase domain: Insights from in silico studies and comparison with experiments.

机构信息

Laufer Center for Physical & Quantitative Biology, Department of Biochemistry and Cell Biology, School of Medicine, Stony Brook University, NY 11794, USA.

Laufer Center for Physical & Quantitative Biology, Department of Pharmacological Sciences, School of Medicine, Stony Brook University, NY 11794, USA.

出版信息

Curr Opin Struct Biol. 2024 Feb;84:102770. doi: 10.1016/j.sbi.2023.102770. Epub 2024 Jan 11.

DOI:10.1016/j.sbi.2023.102770
PMID:38211377
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11044982/
Abstract

The eukaryotic protein kinase domain has been a broadly explored target for drug discovery, despite limitations imposed by its high sequence conservation as a shared modular domain and the development of resistance to drugs. One way of addressing those limitations has been to target its potential allosteric sites, shortly called allo-targeting, in conjunction with, or separately from, its conserved catalytic/orthosteric site that has been widely exploited. Allosteric regulation has gained importance as an alternative to overcome the drawbacks associated with the indiscriminate effect of targeting the active site, and it turned out to be particularly useful for these highly promiscuous and broadly shared kinase domains. Yet, allo-targeting often faces challenges as the allosteric sites are not as clearly defined as its orthosteric sites, and the effect on the protein function may not be unambiguously assessed. A robust understanding of the consequence of site-specific allo-targeting on the conformational dynamics of the target protein is essential to design effective allo-targeting strategies. Recent years have seen important advances in in silico identification of druggable sites and distinguishing among them those sites expected to allosterically mediate conformational switches essential to signal transmission. The present opinion underscores the utility of such computational approaches applied to the kinase domain, with the help of comparison between computational predictions and experimental observations.

摘要

真核蛋白激酶结构域一直是药物发现的广泛探索靶点,尽管其作为共享模块域的高序列保守性以及对药物产生耐药性带来了限制。解决这些限制的一种方法是靶向其潜在的变构结合位点,简称变构靶向,与广泛利用的保守催化/正位结合位点结合或分开。变构调节作为克服靶向活性位点相关缺点的替代方法变得越来越重要,对于这些高度混杂和广泛共享的激酶结构域尤其有用。然而,变构靶向常常面临挑战,因为变构结合位点不如其正位结合位点那样明确,并且对蛋白质功能的影响可能无法明确评估。深入了解特定部位的变构靶向对靶蛋白构象动力学的影响,对于设计有效的变构靶向策略至关重要。近年来,在计算上识别可成药的变构结合位点并区分那些有望变构介导对信号转导至关重要的构象开关的变构结合位点方面取得了重要进展。本观点强调了在激酶结构域中应用此类计算方法的实用性,通过计算预测与实验观察之间的比较来实现。

相似文献

1
Allo-targeting of the kinase domain: Insights from in silico studies and comparison with experiments.激酶结构域的 allo 靶向:计算研究的见解及与实验的比较。
Curr Opin Struct Biol. 2024 Feb;84:102770. doi: 10.1016/j.sbi.2023.102770. Epub 2024 Jan 11.
2
Computational Tools for Allosteric Drug Discovery: Site Identification and Focus Library Design.变构药物发现的计算工具:位点识别与聚焦文库设计
Methods Mol Biol. 2017;1529:439-446. doi: 10.1007/978-1-4939-6637-0_23.
3
Allo-network drugs: extension of the allosteric drug concept to protein- protein interaction and signaling networks.别构网络药物:将别构药物概念扩展到蛋白质-蛋白质相互作用和信号网络。
Curr Top Med Chem. 2013;13(1):64-77. doi: 10.2174/1568026611313010007.
4
Allosteric Methods and Their Applications: Facilitating the Discovery of Allosteric Drugs and the Investigation of Allosteric Mechanisms.变构方法及其应用:促进变构药物的发现和变构机制的研究。
Acc Chem Res. 2019 Feb 19;52(2):492-500. doi: 10.1021/acs.accounts.8b00570. Epub 2019 Jan 28.
5
Advances in the Computational Identification of Allosteric Sites and Pathways in Proteins.蛋白质别构位点和通路的计算鉴定进展。
Adv Exp Med Biol. 2019;1163:141-169. doi: 10.1007/978-981-13-8719-7_7.
6
Druggable orthosteric and allosteric hot spots to target protein-protein interactions.可靶向蛋白质-蛋白质相互作用的可成药正构和变构热点。
Curr Pharm Des. 2014;20(8):1293-301. doi: 10.2174/13816128113199990073.
7
Assessing the structural conservation of protein pockets to study functional and allosteric sites: implications for drug discovery.评估蛋白质口袋的结构保守性以研究功能和变构位点:对药物发现的启示
BMC Struct Biol. 2010 Mar 31;10:9. doi: 10.1186/1472-6807-10-9.
8
Systematic discovery of molecular probes targeting multiple non-orthosteric and spatially distinct sites in the botulinum neurotoxin subtype A (BoNT/A).针对肉毒杆菌神经毒素A亚型(BoNT/A)中多个非正构且空间上不同位点的分子探针的系统性发现。
Mol Cell Probes. 2015 Jun;29(3):135-43. doi: 10.1016/j.mcp.2015.02.002. Epub 2015 Mar 4.
9
Recent Advances in the Discovery of CK2 Allosteric Inhibitors: From Traditional Screening to Structure-Based Design.近年来 CK2 变构抑制剂发现的进展:从传统筛选到基于结构的设计。
Molecules. 2020 Feb 16;25(4):870. doi: 10.3390/molecules25040870.
10
Recent computational advances in the identification of allosteric sites in proteins.蛋白质变构位点识别方面的最新计算进展。
Drug Discov Today. 2014 Oct;19(10):1595-600. doi: 10.1016/j.drudis.2014.07.012. Epub 2014 Aug 11.

引用本文的文献

1
Leveraging artificial intelligence and machine learning in kinase inhibitor development: advances, challenges, and future prospects.在激酶抑制剂开发中利用人工智能和机器学习:进展、挑战及未来前景。
RSC Med Chem. 2025 Aug 12. doi: 10.1039/d5md00494b.
2
How residence time works in allosteric drugs.变构药物中的驻留时间是如何起作用的。
Curr Opin Struct Biol. 2025 Aug 29;94:103149. doi: 10.1016/j.sbi.2025.103149.
3
Advancements in Protein Kinase Inhibitors: From Discovery to Clinical Applications.蛋白激酶抑制剂的进展:从发现到临床应用。

本文引用的文献

1
Conformation selection by ATP-competitive inhibitors and allosteric communication in ERK2.ERK2 中 ATP 竞争抑制剂和别构通讯的构象选择。
Elife. 2024 Mar 27;12:RP91507. doi: 10.7554/eLife.91507.
2
Systematic Analysis of Covalent and Allosteric Protein Kinase Inhibitors.系统分析共价和别构蛋白激酶抑制剂。
Molecules. 2023 Aug 1;28(15):5805. doi: 10.3390/molecules28155805.
3
Application of Radiomics in Prognosing Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis.
Research (Wash D C). 2025 Jun 21;8:0747. doi: 10.34133/research.0747. eCollection 2025.
4
Tilting the Scales toward EGFR Mutant Selectivity: Expanding the Scope of Bivalent "Type V" Kinase Inhibitors.向表皮生长因子受体(EGFR)突变选择性倾斜天平:扩展二价“V型”激酶抑制剂的范围
J Med Chem. 2024 Dec 12;67(23):21438-21469. doi: 10.1021/acs.jmedchem.4c02311. Epub 2024 Dec 3.
5
Global hinge sites of proteins as target sites for drug binding.蛋白质的全局铰链位点作为药物结合的靶位点。
Proc Natl Acad Sci U S A. 2024 Dec 3;121(49):e2414333121. doi: 10.1073/pnas.2414333121. Epub 2024 Nov 25.
放射组学在预测接受表皮生长因子受体酪氨酸激酶抑制剂治疗的肺癌中的应用:一项系统评价和荟萃分析
Cancers (Basel). 2023 Jul 8;15(14):3542. doi: 10.3390/cancers15143542.
4
Design of allosteric sites into rotary motor V-ATPase by restoring lost function of pseudo-active sites.通过恢复伪活性位点丧失的功能,在旋转式马达 V-ATPase 中设计别构位点。
Nat Chem. 2023 Nov;15(11):1591-1598. doi: 10.1038/s41557-023-01256-4. Epub 2023 Jul 6.
5
Crystal structure of the kinase domain of a receptor tyrosine kinase from a choanoflagellate, Monosiga brevicollis.海绵动物动吻动物门小眼虫属受体酪氨酸激酶激酶结构域的晶体结构。
PLoS One. 2023 Jun 13;18(6):e0276413. doi: 10.1371/journal.pone.0276413. eCollection 2023.
6
Bruton's tyrosine kinase inhibitors in the treatment of multiple sclerosis.布鲁顿酪氨酸激酶抑制剂在多发性硬化症治疗中的应用
Postep Psychiatr Neurol. 2023 Mar;32(1):23-30. doi: 10.5114/ppn.2023.126319. Epub 2023 Mar 30.
7
Decoding the mechanisms of allostery.解析变构作用的机制。
Elife. 2023 Jun 2;12:e88749. doi: 10.7554/eLife.88749.
8
Pharmacological hallmarks of allostery at the M4 muscarinic receptor elucidated through structure and dynamics.通过结构和动力学研究揭示 M4 毒蕈碱受体变构作用的药理学特征。
Elife. 2023 May 30;12:e83477. doi: 10.7554/eLife.83477.
9
Structural mechanism of a drug-binding process involving a large conformational change of the protein target.涉及蛋白质靶标大构象变化的药物结合过程的结构机制。
Nat Commun. 2023 Apr 5;14(1):1885. doi: 10.1038/s41467-023-36956-5.
10
Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario.靶向小儿肿瘤学中被劫持的激酶信号通路:机遇与现状
Pharmaceutics. 2023 Feb 16;15(2):664. doi: 10.3390/pharmaceutics15020664.